NO20045359L - Hydroksy-tetrahydro-naftalenylureaderivater - Google Patents

Hydroksy-tetrahydro-naftalenylureaderivater

Info

Publication number
NO20045359L
NO20045359L NO20045359A NO20045359A NO20045359L NO 20045359 L NO20045359 L NO 20045359L NO 20045359 A NO20045359 A NO 20045359A NO 20045359 A NO20045359 A NO 20045359A NO 20045359 L NO20045359 L NO 20045359L
Authority
NO
Norway
Prior art keywords
tetrahydro
pain
useful
treatment
naphthalene derivatives
Prior art date
Application number
NO20045359A
Other languages
English (en)
Inventor
Takeshi Yura
Toshio Kokubo
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Tsutomu Masuda
Klaus Urbahns
Hiroshi Fujishima
Toshiya Moriwaki
Masahiro Shiroo
Masaomi Tajimi
Yasuhiro Tsukimi
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0210512.0A external-priority patent/GB0210512D0/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20045359L publication Critical patent/NO20045359L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår tefrahydro-naftalenderivater og salter derav som er anvendehge som aktive ingredienser i farmasøytiske preparater. Tefrahydro-naftalenderivatene ifølge oppfmnelsen har en svært god aktivitet som VRI antagonist og anvendelig for profylakse og behandling av sykdorrmier assosiert med VRI aktivitet, særlig for behandling av frengende urininkontinens, overaktiv blære, kronisk smerte, neuropatisk smerte, postoperativ smerte, reumatoid artrittsmerte, neuralgi, neuropati, algesi, nerveskade, ishemi, neurodegenerasjon, slag, inkontinens, inflammasjonsforstyrrelser slike som astina og eOPD.
NO20045359A 2002-05-08 2004-12-07 Hydroksy-tetrahydro-naftalenylureaderivater NO20045359L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210512.0A GB0210512D0 (en) 2002-05-08 2002-05-08 Tetrahydro-napthalene derivatives
GBGB0227262.3A GB0227262D0 (en) 2002-05-08 2002-11-21 Tetrahydro-naphthalene derivatives
PCT/EP2003/004395 WO2003095420A1 (en) 2002-05-08 2003-04-28 Hydroxy tetrahydro-naphthalenylurea derivatives

Publications (1)

Publication Number Publication Date
NO20045359L true NO20045359L (no) 2004-12-07

Family

ID=29422108

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045359A NO20045359L (no) 2002-05-08 2004-12-07 Hydroksy-tetrahydro-naftalenylureaderivater

Country Status (21)

Country Link
US (1) US7612113B2 (no)
EP (1) EP1506167B1 (no)
JP (1) JP4335131B2 (no)
CN (1) CN1307150C (no)
AT (1) ATE371641T1 (no)
AU (1) AU2003229734B2 (no)
BR (1) BR0309940A (no)
CA (1) CA2487238C (no)
DE (1) DE60315973T2 (no)
DK (1) DK1506167T3 (no)
ES (1) ES2292959T3 (no)
HK (1) HK1082946A1 (no)
HR (1) HRP20041167A2 (no)
IL (1) IL165004A (no)
MX (1) MXPA04010938A (no)
NO (1) NO20045359L (no)
NZ (1) NZ536418A (no)
PL (1) PL210288B1 (no)
RU (1) RU2331635C2 (no)
TW (1) TWI271396B (no)
WO (1) WO2003095420A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028440A2 (en) * 2002-09-24 2004-04-08 Bayer Healthcare Ag Vr1 antagonists for the treatment of urological disorders
WO2004052846A1 (en) 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
JP4440113B2 (ja) * 2002-12-09 2010-03-24 バイエル・ヘルスケア・アクチェンゲゼルシャフト バニロイド受容体アンタゴニストとしてのテトラヒドロ−ナフタレン誘導体
WO2005035471A1 (ja) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. エーテル誘導体
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
CA2545109A1 (en) * 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives
WO2005095329A1 (en) * 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
JP2008532956A (ja) * 2005-03-05 2008-08-21 バイエル・ヘルスケア・アクチェンゲゼルシャフト ヒドロキシテトラヒドロ−ナフタレン誘導体の使用
EP1861357B1 (en) 2005-03-19 2013-04-24 Amorepacific Corporation Novel compounds or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
DE102005017286B3 (de) * 2005-04-14 2006-12-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
EP2450346A1 (en) 2006-12-20 2012-05-09 Abbott Laboratories Antagonists of the TRPV1 receptor and uses thereof
WO2008096755A1 (ja) * 2007-02-07 2008-08-14 Nippon Suisan Kaisha, Ltd. バニロイド受容体（ｖｒ１）阻害剤及びその用途
DE102009055915A1 (de) * 2009-11-27 2011-06-01 Beiersdorf Ag Verwendung von Zingeron zur Herstellung kosmetischer oder dermatologischer Zubereitungen, welche auf der Haut ein Prickeln hervorrufen
JP6830569B1 (ja) 2019-08-23 2021-02-17 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
ES2253208T3 (es) * 1999-02-22 2006-06-01 Pacific Corporation Analogos de vaniloide que contienen farmacoforos de resiniferatoxina como ponentes agonistas del receptor de vaniloide y analgesicos, composiciones y utilizaciones de los mismos.
AU757729B2 (en) 1999-04-07 2003-03-06 Sankyo Company Limited Amine derivatives
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
WO2004052846A1 (en) * 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
CA2545100A1 (en) * 2003-11-08 2005-05-19 Bayer Healthcare Ag Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators

Also Published As

Publication number Publication date
NZ536418A (en) 2006-04-28
EP1506167A1 (en) 2005-02-16
HK1082946A1 (en) 2006-06-23
AU2003229734B2 (en) 2009-02-19
CN1307150C (zh) 2007-03-28
TWI271396B (en) 2007-01-21
PL210288B1 (pl) 2011-12-30
CA2487238A1 (en) 2003-11-20
RU2331635C2 (ru) 2008-08-20
US20060258742A1 (en) 2006-11-16
HRP20041167A2 (en) 2005-08-31
MXPA04010938A (es) 2005-02-14
DK1506167T3 (da) 2008-01-02
ES2292959T3 (es) 2008-03-16
DE60315973T2 (de) 2008-05-21
CA2487238C (en) 2011-03-22
IL165004A0 (en) 2005-12-18
RU2004136281A (ru) 2005-07-10
IL165004A (en) 2010-12-30
PL373257A1 (en) 2005-08-22
AU2003229734A1 (en) 2003-11-11
TW200404052A (en) 2004-03-16
BR0309940A (pt) 2005-02-09
WO2003095420A1 (en) 2003-11-20
JP4335131B2 (ja) 2009-09-30
DE60315973D1 (de) 2007-10-11
EP1506167B1 (en) 2007-08-29
ATE371641T1 (de) 2007-09-15
JP2005524717A (ja) 2005-08-18
CN1665778A (zh) 2005-09-07
US7612113B2 (en) 2009-11-03

Similar Documents

Publication Publication Date Title
HK1082946A1 (en) Hydroxy tetrahydro-naphthalenyurea derivatives
DK1569896T3 (da) Tetrahydronaphthalenderivater
WO2003055848A3 (en) Urea derivatives as vr1- antagonists
WO2003014064A8 (en) Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
WO2004092115A3 (en) Hydroxamates as therapeutic agents
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
DK1572632T3 (da) Tetrahydro-naphthalenderivater som vanilloidreceptorantagonister
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
GB2427405A (en) Novel hydroxamates as therapeutic agents
WO2007053499A3 (en) Compounds useful as antagonists of ccr2
WO2011045068A3 (en) Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
SE0401655D0 (sv) New compounds
MX2009011818A (es) Formulaciones de aminoacido n-halogenado con compuestos anti-inflamatorios.
TW200716629A (en) Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof
MY155011A (en) Hydroxy tetrahydro-naphthalenylurea derivatives
UY27794A1 (es) Derivados de hidroxi tetrahidro-naftalenilurea
TH78306A (th) อนุพันธ์ไฮดรอกซีเททตราไฮโดร-แนพธาลีนิลยูเรีย
TH78306B (th) "อนุพันธ์ไฮดรอกซีเททตราไฮโดร-แนพธาลีนิลยูเรีย"
EA200501765A2 (ru) Средство для лечения болезней суставов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application